IMA has helped countries including Haiti, Tanzania, South Sudan and Democratic Republic of Congo (DRC) take significant steps towards NTD elimination through mass drug administration (MDA) and treatment.
In South Sudan, IMA now partners with the END Fund to build on more than seven years of IMA-supported national efforts to combat visceral leishmaniasis (VL). VL, also known as kala-azar, is a debilitating, and if left untreated, fatal NTD that over two million people are at risk of contracting across South Sudan. By joining with the END Fund, IMA is advancing local leadership by strengthening health systems for VL control as well as integrating VL diagnosis and treatment in 21 primary health care facilities in disease-prevalent counties.
In Tanzania, with support from SCI Foundation and in collaboration with the National NTD Control Program of Tanzania’s Ministry of Health, IMA conducted MDAs of school-aged children and implemented related activities for schistosomiasis (SCH) and soil-transmitted helminthiasis (STH) prevention and treatment in 93 districts across 15 regions. Despite challenges posed by the COVID-19 pandemic, the project reached over 5,122,000 children and achieved a 95 percent MDA coverage rate.
By partnering with the Ministry of Health in Tanzania, Dr. Lali Chania, our Tanzania Country Director, explains how IMA trained over 118,000 frontline health workers, government officials, community drug distributors and volunteers to conduct mass drug administration in our effort to prevent NTDs and improve health service delivery.